Loading organizations...
Based in New York, New York, Caladan Bio develops modular benchtop bioreactors and AI-driven software platforms designed to accelerate bioprocessing and synthetic biology research. The company provides affordable hardware integrated with its proprietary CaladanOS system and advanced sensor technology, enabling high-throughput experimentation, data optimization, and faster scale-up from laboratory settings to commercial production. These automated systems are utilized by biotechnology laboratories, corporate innovators, and researchers focused on developing novel medicines, bioplastics, sustainable materials, and other biomanufacturing products. To support its ongoing hardware and software development, Caladan Bio has raised $5.11 million in seed funding and recently filed for a $30 million offering. The organization is backed by a syndicate of prominent venture capital investors, including Collab Fund, Twelve Below, Wireframe, and Lerer Hippeau. The enterprise was established in 2023 by co-founders Michael Kobida and Rob Jauquet.
Caladan Bio has raised $5.0M across 1 funding round.
Caladan Bio has raised $5.0M in total across 1 funding round.
Caladan Bio has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in May 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2024 | $5M Seed | Twelve Below | Collaborative Fund, Factorial Capital, Lerer Hippeau, Ritual Capital, Wireframe Ventures | Announced |
Caladan Bio has raised $5.0M in total across 1 funding round.
Caladan Bio's investors include Twelve Below, Collaborative Fund, Factorial Capital, Lerer Hippeau, Ritual Capital, Wireframe Ventures.
